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2 
Abstract 23 
Isopentenol (or isoprenol, 3-methyl-3-buten-1-ol) is a drop-in biofuel and a precursor for 24 
commodity chemicals such as isoprene. Biological production of isopentenol via the mevalonate 25 
pathway has been optimized extensively in Escherichia coli, yielding 70% of its theoretical 26 
maximum. However, high ATP requirements and isopentenyl diphosphate (IPP) toxicity pose 27 
immediate challenges for engineering bacterial strains to overproduce commodities utilizing IPP 28 
as an intermediate. To overcome these limitations, we developed an “IPP-bypass” isopentenol 29 
pathway using the promiscuous activity of a mevalonate diphosphate decarboxylase (PMD) and 30 
demonstrated improved performance under aeration-limited conditions. However, relatively low 31 
activity of PMD toward the non-native substrate (mevalonate monophosphate, MVAP) was 32 
shown to limit flux through this new pathway. By inhibiting all IPP production from the 33 
endogenous non-mevalonate pathway, we developed a high-throughput screening platform that 34 
correlated promiscuous PMD activity toward MVAP with cellular growth. Successful 35 
identification of mutants that altered PMD activity demonstrated the sensitivity and specificity of 36 
the screening platform. Strains with evolved PMD mutants and the novel IPP-bypass pathway 37 
increased titers up to 2.4-fold. Further enzymatic characterization of the evolved PMD variants 38 
suggested that higher isopentenol titers could be achieved either by altering residues directly 39 
interacting with substrate and cofactor or by altering residues on nearby α-helices. These altered 40 
residues could facilitate the production of isopentenol by tuning either kcat or Ki of PMD for the 41 
non-native substrate. The synergistic modification made on PMD for the IPP-bypass mevalonate 42 
pathway is expected to significantly facilitate the industrial scale production of isopentenol. 43 
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1 Introduction 45 
Isopentenol (or isoprenol, 3-methyl-3-buten-1-ol) is a promising biofuel and a precursor 46 
for industrial chemicals such as isoprene (Beller et al., 2015; George et al., 2015a). The research 47 
octane number of isopentenol (98) is close to isooctane (RON = 100), demonstrating its potential 48 
use as an anti-knocking additive in gasoline (Liu et al., 2014; Mack et al., 2014). Several 49 
microbial hosts have been engineered for biological production of isopentenol with the most 50 
commonly targeted pathways including isoprenoid pathways from both the mevalonate (MVA) 51 
pathway and the methylerythritol phosphate (MEP) pathway, and the keto acid pathway (Atsumi 52 
et al., 2008). 53 
Briefly, the conventional MVA pathway for isopentenol production starts with reactions 54 
that condense three acetyl-CoA molecules and produce one molecule of MVA. Next, mevalonate 55 
kinase (MK) phosphorylates MVA to mevalonate 5-phosphate (MVAP), which is subsequently 56 
phosphorylated to mevalonate 5-diphosphate (MVAPP, also diphosphomevalonate) by 5-57 
phosphomevalonate kinase (PMK). The phosphorylation reactions consume two adenosine 58 
triphosphate (ATP) molecules, and then diphosphomevalonate decarboxylase (PMD) converts 59 
MVAPP to isopentenyl diphosphate (IPP) while consuming one additional ATP molecule (Figure 60 
1A). Lastly, isopentenol is produced by hydrolysis of the pyrophosphate group from IPP (Chou 61 
and Keasling, 2012). 62 
Extensive optimization of the conventional MVA pathway for isopentenol production in 63 
Escherichia coli resulted in titers of 2.2 g/L with 70% of apparent theoretical yield (George et al., 64 
2014; George et al., 2015b). However, the “IPP-dependency” of the conventional MVA pathway 65 
intrinsically limits engineering of the MVA pathway toward high titer isopentenol production for 66 
two primary reasons: its high ATP requirement and toxicity of IPP (Kang et al., 2016). First, 67 
generation of one molecule of IPP via the MVA pathway requires the consumption of 3 ATP 68 
molecules, which accounts for approximately 5.3% of the theoretical ATP yield from complete 69 
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aerobic respiration of one and half (1.5) molecules of glucose. However, in the conventional 70 
MVA-based isopentenol production pathway, the hydrolysis of the diphosphate group of IPP 71 
squanders cellular ATP, underscoring the importance of constructing more energetically efficient 72 
pathways for isopentenol production. Secondly, accumulation of IPP has been proposed to inhibit 73 
growth of E. coli (George et al., 2015b; Kang et al., 2016; Martin et al., 2003). Although specific 74 
molecular mechanisms behind the growth inhibition effects of IPP are not clear yet, general stress 75 
responses accompanied with the growth inhibition potentially divert carbon flux away from 76 
desired isopentenol production (Adolfsen and Brynildsen, 2015; Cohen, 2014; Hengge, 2008; 77 
Kang et al., 2016; Sun et al., 2011). Since IPP is an essential precursor for isopentenol production 78 
in the MVA pathway, maintaining IPP at the optimal level is critical for efficient isopentenol 79 
production while minimizing the growth inhibition by excessive IPP. Therefore, “IPP-80 
dependency” of the MVA pathway makes the engineering of the conventional IPP-dependent 81 
MVA pathway for isopentenol production more complicated and inefficient. 82 
To overcome the limitations of the IPP-dependent conventional MVA pathway, an IPP-83 
bypass MVA pathway has been developed (Kang et al., 2016) (Figure 1A). A heterologously 84 
expressed Saccharomyces cerevisiae PMD enzyme (PMDsc) promiscuously decarboxylates 85 
MVAP to form isopentenyl phosphate (IP), which is hydrolyzed to isopentenol by endogenous 86 
phosphatases. This novel IPP-bypass MVA pathway significantly reduced IPP toxicity and made 87 
isopentenol production more robust relative to the native MVA pathway under aeration-limited 88 
conditions by decreasing ATP consumption (Kang et al., 2016). Despite its lower toxicity and 89 
higher energetic efficiency, isopentenol production via the IPP-bypass MVA pathway was limited 90 
by relatively low activity of PMDsc toward the alternative substrate, MVAP (kcat = 0.14 sec-1) 91 
compared to the activity toward MVAPP, the original substrate (kcat = 5.4 sec-1) (Kang et al., 92 
2016; Krepkiy and Miziorko, 2004). Therefore, engineering PMD to be more active toward 93 
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MVAP is necessary to relieve the bottleneck and increase isopentenol titers and productivity of 94 
the IPP-bypass isopentenol pathway. 95 
With this goal, we developed a growth-linked selection method to screen PMD mutants 96 
with improved activity toward MVAP. In this new screening platform, we coupled PMDsc 97 
substrate promiscuity to the formation of IPP and dimethylallyl pyrophosphate (DMAPP), 98 
essential metabolites for E. coli growth. IPP production from the endogenous MEP pathway was 99 
eliminated by supplementing an antibiotic that inhibits the MEP pathway. E. coli growth was 100 
rescued only by co-expression of the heterologous IPP-bypass pathway containing sufficiently 101 
active PMDsc to convert MVAP to IP with isopentenyl phosphate kinase (IPK), which produces 102 
IPP from IP. Using the growth-linked screening platform, we evaluated libraries of PMD variants 103 
and identified mutations that improve isopentenol production in E. coli via the IPP-bypass MVA 104 
pathway. 105 
2 Results and Discussion 106 
2.1 Design of screening platform and optimization 107 
We designed the screening platform in which the growth rate of the host strain is coupled 108 
to the decarboxylation rate of the PMD enzyme (Figure 1B). To link cellular growth rates directly 109 
with MVAP decarboxylation rates, IPP produced via the endogenous MEP pathway should be 110 
blocked either by gene knock-out or by inhibition. Genes involved in the MEP pathway, however, 111 
are essential for E. coli growth (Heuston et al., 2012), making development of a knockout mutant 112 
difficult. Therefore, we chose the second option that is to inhibit the MEP pathway by the 113 
addition of the MEP pathway inhibitor fosmidomycin (Zhang et al., 2011). Fosmidomycin is an 114 
antibiotic that inhibits 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) of the MEP 115 
pathway in native E. coli, and it ultimately blocks the only route to generate IPP and DMAPP. By 116 
adding fosmidomycin to the cultures of the screening platform strain, isoprenoids for E. coli 117 
growth could solely be derived from carbon flux through the heterologously expressed IPP-118 
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bypass MVA pathway in the presence of an adequate enzyme to convert IP to IPP. In nature, 119 
archaea have a unique isoprenoid pathway where IP is phosphorylated to IPP by IP kinase (Chen 120 
and Poulter, 2010). In our screening platform, archaeal IP kinases (IPK) were heterologously 121 
expressed to generate IPP via phosphorylation of IP produced from the IPP-bypass MVA 122 
pathway (Figure 1B). 123 
We tested for fosmidomycin sensitivity by introducing various amounts of fosmidomycin 124 
into DH1, BW25113 and BL21 (Supplementary Table S1), three E. coli strains commonly used 125 
for microbial metabolic engineering. DH1 was significantly more susceptible than the other two 126 
strains (Supplementary Figure S1) to fosmidomycin, as it was the only strain that had no growth 127 
on 10 µM fosmidomycin. At higher concentrations of fosmidomycin, cell death was accelerated 128 
in DH1, supported by a fast reduction in optical density (OD) at 600 nm after approximately two 129 
hours of exposure to fosmidomycin. On the other hand, both BL21 and BW25113 continued to 130 
grow for approximately four hours when exposed to equivalent fosmidomycin levels 131 
(Supplementary Figure S1). Therefore, DH1 was selected as a host strain to screen PMD mutants 132 
for improved MVAP decarboxylation activity and subsequent isopentenol production in this 133 
study. 134 
We subsequently confirmed that growth inhibited by fosmidomycin resumed in DH1 by 135 
allowing IPP production from IP, which is generated via the IPP-bypass MVA pathway (Figure 136 
1). Three kinases with previously reported activity towards IP—IspE from E. coli (EcIPK) 137 
(Lange and Croteau, 1999) and two archaeal IP kinases (Funke et al., 2010) from 138 
Methanothermobacter thermautotrophicus (MtIPK) and Thermoplasma acidophilum (TaIPK) —139 
were heterologously expressed (JBEI-15323, JBEI-15642 and JBEI-15350, respectively) in DH1 140 
together with wild type PMDsc (JBEI-15645). Expression of two archaeal IP kinases, MtIPK, and 141 
TaIPK, enabled growth recovery of the DH1 strains under fosmidomycin selection pressure, 142 
suggesting higher kinase activity of MtIPK and TaIPK compared to that of EcIPK (Figure 2A). 143 
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Between two strains expressing the archaeal IPKs, the strain that expressed the MtIPK showed a 144 
shorter lag phase (2 hours vs 3-4 hours) regardless of expression level of PMDsc (10 or 100 nM 145 
anhydrotetracycline (aTc)) (Lee et al., 2011), suggesting that MtIPK provides better sensitivity to 146 
the screening platform. On the other hand, when an inactive mutant, PMDsc-S208E (Kang et al., 147 
2016), was co-expressed (JBEI-15647), none of three IPK-expressing DH1 strains (SP4, SP5 and 148 
SP6, Supplementary Table S1) could grow. This result supports our screening platform design 149 
hypothesis, which implies that cellular growth is solely dependent upon decarboxylation of 150 
MVAP within the heterologously expressed IPP-bypass pathway. In addition, resistance to 151 
fosmidomycin, which could be developed by adaptive mutations (Martinez and Baquero, 2000), 152 
was not observed under the condition of the screening platform and during growth recovery 153 
experiments. 154 
After optimizing the screening conditions where E. coli DH1 can survive only from IPP 155 
produced from IP generated solely from the MVA pathway, we tested whether the growth rate of 156 
E. coli DH1 correlated with the relative enzyme activity of PMDsc on MVAP. The kinetics of six 157 
PMDsc variants (K22M, R74H, I145F, T209D, S155E and S208E) revealed that two mutants, 158 
K22M and R74H, were shown to either decrease or increase isopentenol titers, respectively, in 159 
accordance with altering kcat or kcat/KM of PMDsc for MVAP (Kang et al., 2016). Therefore, the 160 
growth rates of K22M and R74H mutants were determined along with positive (WT PMDsc) and 161 
negative (inactive S208E mutant) controls under the screening conditions. 162 
As shown in Figure 2b and Supplementary Figure S2, the growth rates of these four 163 
strains varied depending on the MVAP decarboxylation activity and expression level of PMDsc. 164 
When these enzyme variants were expressed at lower inducer concentrations (10 nM aTc; 165 
Supplementary Figure S2a) or with low copy number plasmids (Figure 2b), the growth rates of 166 
the DH1 strains harboring the corresponding screening plasmids were dependent on the MVAP-167 
decarboxylation activity of PMDsc variants. Strains with R74H grew faster than the strain with 168 
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WT PMDsc, while strain harboring the K22M mutant exhibited decreased growth rates relative to 169 
wild type. In addition, it was confirmed that a strain harboring wild type PMDsc grew at different 170 
rates when the PMDsc was expressed at different inducer concentrations (data not shown). 171 
However, when protein expression levels of PMD variants were increased by using 10-fold 172 
higher inducer concentrations (100 nM aTc), all E. coli DH1 with active PMDsc variants K22M, 173 
R74H, and WT showed similar growth rates (0.83  .01 hr-1) (Supplementary Figure S2). This 174 
result suggests that expression of PMD needs to be tightly regulated to keep the sensitivity of the 175 
screening platform such that the selection pressure would reflect the relative catalytic activity of 176 
PMDsc mutants. 177 
Subsequently, the sensitivity and selectivity of the screening platform was further verified 178 
by competitive growth among the three DH1 strains containing PMDsc WT, K22M and R74H. A 179 
mixed seed culture was prepared by combining an equal starting amount of each of the three 180 
strains and incubated overnight. The mixed population was diluted and regrown in fresh medium 181 
supplemented with 10 μM fosmidomycin. Sequencing data revealed that DH1 expressing 182 
PMDsc-R74H was the dominant strain present after several dilutions of the mixed culture 183 
(Supplementary Figure S3). Again, this result confirmed that the screening platform selects for 184 
PMDsc mutants with increased activity among a mixed population of strains via growth 185 
competition. 186 
2.2 Screening of saturation mutagenesis libraries 187 
After testing selectivity of the screening platform, we constructed and tested two sets of 188 
libraries of PMDsc mutants: one library was constructed by codon saturation mutagenesis on 189 
seven rationally targeted residues and the other was constructed by error-prone PCR to generate 190 
random mutations in PMDsc. 191 
Five residues (Tyr19, Lys22, Ser208, Thr209 and Met212) were selected for codon 192 
saturation mutagenesis (Figure 3a). Although a crystal structure of PMDsc with a substrate analog 193 
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is not available, structural alignment of PMDsc (1FI4) (Bonanno et al., 2001) with a homologous 194 
PMD isolated from Staphylococcus epidermidis (PMDse) revealed several parallels between their 195 
active sites (Barta et al., 2011). Tyr19 and Lys22 in PMDsc correspond to Tyr18 and Lys21 in 196 
PMDse, and these homologous residues most likely interact with the pyrophosphate group of the 197 
native substrate, MVAPP. The hydroxyl side chain of Ser208 in PMDsc (Ser192 in PMDse) is 198 
appropriately positioned to form hydrogen bonds with the -phosphate moieties of bound ATP 199 
and MVAPP in the ternary complex model of PMDse (Barta et al., 2012). Thr209 and Met212 of 200 
PMDsc, which correspond to Arg193 and Met196 in PMDse, provide second-sphere structural 201 
support for the residues directly interacting with active site substrates (Figure 3a). Two additional 202 
residues, Arg74 and Ile145, were also selected based on the previous kinetic data implicating 203 
their potential to increase the decarboxylase activity of PMDsc (Kang et al., 2016). R74H and 204 
I145F increased kcat for decarboxylation of multiple substrates in PMDsc, including 3-hydroxy-3-205 
methylbutyrate (Gogerty and Bobik, 2010) and MVAP (Kang et al., 2016). 206 
Screening of the codon saturation mutagenesis libraries resulted in a dominant amino acid 207 
for each residue of Arg74, Ile145, Ser208 and Met212, but the selective effects on the other three 208 
residues, Tyr19, Lys22 and Thr209 were not clear and the sequencing result still showed mixed 209 
signals of all nucleotides. Three of the four dominant residues, Arg74, Ile145 and Met212, were 210 
substituted to serine, alanine and methionine respectively, and we found that these three 211 
mutations (M212Q, R74S, and I145A) significantly improved isopentenol production via the IPP-212 
bypass MVA pathway (Figure 3b). DH1 strains expressing these three mutants significantly 213 
increased isopentenol production relative to WT (475.1 mg/L), with titers ranging from 600-800 214 
mg/L. Such improvement is in line with increases found in R74H (770.3 mg/L) from our previous 215 
study (Kang et al., 2016). Interestingly, combinations of select double mutants, R74S-I145A, 216 
R74S-M212Q, and R74H-M212Q, significantly increased isopentenol titers by up to 2.4-fold 217 
relative to wild type: strains containing these double mutants further improved titers from 900-218 
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1130 mg/L 48 hours after induction with IPTG (Figure 4). Selection of seven codon saturation 219 
mutagenesis libraries successfully demonstrated that the screening platform could identify 220 
PMDsc mutants that have potentially higher activity towards MVAP and increased isopentenol 221 
titers from the IPP-bypass MVA pathway. 222 
In addition to finding mutated residues improving isopentenol production in the IPP-223 
bypass pathway, it also confirmed that the screening platform effectively inhibits the growth of 224 
the strain with inactive PMD variants. Alignment-based structural predictions mapping PMDsc to 225 
a crystal structure of PMDse suggest that Ser208 forms essential hydrogen bonds with both the α-226 
phosphate of ATP and the α-phosphate of MVAPP. We showed that S208E is inactive toward 227 
MVAP (Kang et al., 2016), and another study reported that S208A compromised the structural 228 
stability of the PMDsc, resulting in protein precipitation (Krepkiy and Miziorko, 2005). 229 
Therefore, viable isopentenol-producing strains retaining the wild-type serine at residue 208 in 230 
PMDsc ensured the selection specificity of the screening platform for active PMD sequences. In 231 
addition to the S208E mutant, we tested another strain harboring an inactive mutant (S155E) of 232 
PMD as a second negative control and reconfirmed the impaired growth phenotype (data not 233 
shown). This further supported the wild type selection result of S208 in the saturation 234 
mutagenesis library. Hence, strain selection is based solely on the enhancement of carbon flux 235 
through the IPP-bypass pathway facilitated by PMDsc activity toward the nonnative MVAP 236 
under the screening conditions. 237 
In contrast, Thr209 could be substituted with any amino acid residue (Supplementary 238 
Figure S5), suggesting that there was much less selection pressure on this residue within this 239 
screening platform. Thr209 of PMDsc is a structurally parallel residue to Arg193 of PMDse, 240 
which has been suggested to stabilize the β-phosphate of MVAPP (Barta et al., 2012). Although it 241 
was initially hypothesized that this residue might be critical to determine substrate promiscuity, it 242 
seems that the decarboxylation activity of PMDsc for MVAP was not significantly affected by 243 
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alterations at residue 209. In accordance with this observation, we have shown that T209D did 244 
not significantly change the isopentenol titer in E. coli (Kang et al., 2016). 245 
2.3 Screening of random mutagenesis libraries 246 
Since the size of the saturation mutagenesis libraries was relatively small (7 x 21 = 147 247 
designs), libraries of randomly mutated PMDsc sequences were prepared by error-prone PCR 248 
(McCullum et al., 2010) to contain low-, mid- and high-mutation rates per coding sequence. The 249 
DH1 strains carrying JBEI-15350 (Supplementary Table S1) and plasmids libraries of randomly 250 
mutated PMDsc were serially diluted into fresh medium containing fosmidomycin to enrich fast-251 
growing strains until the growth rate did not significantly vary among all libraries. In total, there 252 
were three rounds of dilutions, but the exposure period of each library to fosmidomycin before 253 
the next round of dilution varied depending on the rate of growth recovery. Given the higher 254 
heterogeneity of initial libraries, the first dilution significantly extended the lag phase during 255 
growth. Thus, all surviving variants after the first selection were rescued overnight in fresh EZ-256 
rich medium without fosmidomycin before the second dilution. At the end of the third dilution, 257 
all libraries exhibited similar growth rates (0.72 ±0.10 h-1), which were higher than the average 258 
growth rate of the second round (0.49 ±0.11 h-1) and comparable to that of R74H (0.68 ± 0.04 h-259 
1). Sequencing of the amplified PMD sequences revealed that two-thirds of tested libraries were 260 
dominated by select PMDsc residues (Table 1), while the remaining mutants were enriched with 261 
the wild type PMDsc. Excluding redundant mutations, six unique PMDsc variants were cloned 262 
into pTrc99a vector, which were in turn co-transformed with JBEI-9310 (Supplementary Table 263 
S1) into DH1 for isopentenol production via the IPP-bypass pathway. Most isopentenol 264 
producing strains with respective PMDsc mutants produced isopentenol at higher titers relative to 265 
wild type PMDsc except V230E. The highest 48-hour post-induction titers were obtained by the 266 
strains with three double mutants, R74G-R147K, Q140L-I226V, and R74G-E144D (Figure 4), 267 
whose titers after 48 hours were 1.9-fold, 1.6-fold, and 1.6-fold higher than the strain with wild 268 
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type PMDsc, respectively. However, not all selected mutations were cooperative for isopentenol 269 
production. R74G and Q140L produced isopentenol at levels similar to or better than those 270 
selected from the randomly mutated libraries, R74G-R147K, Q140L-I226Vand R74G-E144D 271 
mutants. 272 
2.4 Correlating screening properties to PMD catalytic activity 273 
The rationale behind the screening platform posits that in vivo MVAP-decarboxylation 274 
activity of PMD in DH1 correlates with the cellular growth rate under conditions where the 275 
endogenous MEP pathway is inhibited by fosmidomycin (Figure 1B). This hypothesis assumes 276 
that the IPP production rate is limited by MVAP-decarboxylation by PMD (Figure 1A). 277 
Isoprenoids are essential for E. coli growth. Therefore, MVAP-decarboxylation activity, which is 278 
determined by the turnover rate of MVAP to IP in vivo, would partially determine the growth rate 279 
of a host strain where PMD variants with varying MVAP-decarboxylation activities are expressed 280 
in the screening platform (Figure 1B). To further support this hypothesis, we determined the 281 
growth rate for twenty mutants that we found in this study under the conditions implemented for 282 
mutant screening. The 20 mutants selected for this analysis were representative of all strains 283 
producing isopentenol via the IPP-bypass route, ranging from 22  8 mg/L (K22Y) to 1,080  30 284 
mg/L (R74H-R147K-M212Q) (Table 2). As seen in Figure 6, a scatter plot relating cellular 285 
growth rates to isopentenol titers shows a positive linear correlation with R2 = 0.72, further 286 
corroborating that MVAP decarboxylation is indeed the rate-limiting step in the engineered IPP-287 
bypass pathway. Given that only 20 mutants were identified in the screening platform, a rather 288 
low R2 value was inevitably obtained. However, it should be noted that the correlation between 289 
growth rate and isopentenol titers is much better for the eight high-producers of isopentenol (the 290 
eight variants at the top right corner), relative to WT (475.1 mg/L and 0.4 h-1, respectively). 291 
Although the wider variation in growth rates was observed for poorly producing strains (e.g. two 292 
variants at left-bottom corner), it is likely that inactive and less active mutants are more subject to 293 
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a growth-inhibited phenotype than for more active mutant primed for growth. While the growth 294 
phenotype and isopentenol formation are both IP-dependent, variations in growth rates are 295 
possible without knowing the kinetic effects of varying IP levels on the growth phenotype within 296 
strains used for the screening platform.  For this reason, we have noticed that several mutants, 297 
particularly with R74S, showed a wider variation in isopentenol titers, possibly due to colony-to-298 
colony variation often observed in over-producing strains. However, these variations found in 299 
growth rates and titers do not compromise the validity of the screen design, which demonstrates 300 
its selectivity for high-producers over low-producers. 301 
2.5 Potential secondary structure effects of the mutated residues 302 
It is noteworthy that this study identified important residues distal to the active site that 303 
enhanced isopentenol production, implicating the possibility that interactions between -helices 304 
could affect the activity of PMDsc for MVAP decarboxylation (Figure 5). The screening platform 305 
revealed that two of these helical residues, Arg74 and Ile145, could tolerate several substitutions 306 
to facilitate enhanced isopentenol production. In addition to the initially reported mutant (R74H), 307 
we found that smaller glycine and serine substitutions were beneficial at position 74, showing that 308 
protonated side chains in this locale are not necessary for improving enzymatic activity. While 309 
I145F was shown to modestly improve enzyme activity in our previous study (Kang et al 2015), 310 
the emergence of I145A from our screening platform showed that packing properties around 311 
position 145 can affect the PMDsc activity toward nonnative substrates. However, it is not clear 312 
how these distal residues increase activity of PMD toward MVAP. Since both Arg74 and Ile145 313 
residues are quite far from the active site (Figure 3a), substitutions at these locales could result in 314 
altered interactions between neighboring -helices. These altered packing modes might cause 315 
alternative kinetic consequences rather than directly impacting substrate binding. Particularly, 316 
Arg74 appears to shield the active site from bulk solvent by interacting with a loop containing 317 
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several substrate binding domain residues (17-33) proposed to be critical for catalysis 318 
(Supplementary Figure S4). 319 
The kinetic impact arising from Ile145 is much less clear, as this residue is more than 15 320 
Å away from the cofactor moiety. Interestingly, we found three additional single mutants 321 
(Q140L, E144D, R147K) that reside near Ile145, and all of them resulted in increased isopentenol 322 
production titers (Figure 4). Gln140, Glu144, Arg147, and Ile145, are all located on α-helix 2 323 
(H2) (Figure 5), and small conformational changes made by these mutants might affect the two 324 
serine residues (Ser120 and Ser121) at C-terminal end of H2. These serine residues provide 325 
essential hydrogen bonds that stabilize MVAP with ATP (Supplementary Figure S6). In addition 326 
to these four residues, we also identified three more distant residues, Gln210, Ile226, and Val230, 327 
located on α-helix 4 (H4) (Figure 5), which could alter substrate binding modes for MVAP. 328 
Since we found a positive correlation between isopentenol titers using mutant PMDs and 329 
their respective growth rates in the screening platform, we initially expected to see a direct 330 
correlation between kinetic parameters (kcat and kcat/KM) of mutant PMDs and either isopentenol 331 
titers or growth rates. However, there was no significant correlation between kinetic activity of 332 
mutants and isopentenol and/or cellular growth rates (Supplementary Figure S7). The kinetics of 333 
fourteen PMDsc variants for enzymatic decarboxylation (Table 2) showed that many mutants 334 
significantly increased kcat/KM for MVAP, which includes kinetic steps associated with substrate 335 
and cofactor binding. However, increasing kcat/KM does not improve growth rates or isopentenol 336 
titers. 337 
The most striking data for kcat/KM arise from the Y19H and M212Q mutants, which are 338 
proposed to interact with the phosphate moieties of the native MVAPP substrate (Figure 3a).  339 
Like other diphosphate decarboxylases, the conserved P-loop motif (Barta et al., 2012; Saraste et 340 
al., 1990) closes upon ATP binding, which then coordinates substrate and cofactor for catalysis 341 
(Barta et al., 2012). Since MVAP lacks the -phosphate group, the active site needs to be more 342 
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compact to prevent packing defects within the active site. In the structural alignment model, the 343 
Met212 residue is less than 4 Å from the predicted binding site of the α-phosphate moiety in 344 
MVAP (Figure 3a). Therefore, its mutation to glutamine (M212Q) could provide additional 345 
hydrogen-bonding interactions with this phosphate moiety to help stabilize MVAP, thereby 346 
increasing kcat/KM (0.5  0.1 mM-1 s-1) (Table 2). 347 
Similarly, we hypothesized that mutations at residue 19 might improve stabilization of α-348 
phosphate based on the previous computational study (Weerasinghe and Samantha Dassanayake, 349 
2010), and therefore we aimed to find a better-positioned residue that might interact with the α-350 
phosphate of MVAP. Indeed, Y19H increased kcat/KM of PMDsc about 10-fold (0.78  0.06 mM-1 351 
s-1) (Table 2) compared to that of wild type, exhibiting the largest increase of kcat/KM relative to 352 
wild type. Although both M212Q and Y19H increased kcat/KM of PMDsc, interestingly only 353 
M212Q could significantly increase isopentenol titer, while Y19H rather significantly decreased 354 
isopentenol titers (Table 2). 355 
Analysis of all characterized mutants revealed that there was no significant correlation 356 
between kcat (or kcat/KM) and the cellular growth rate or the isopentenol titer (Supplementary 357 
Figure S7). For example, the activity of a triple mutant, R74G-R147K-M212Q (kcat/KM = 0.5  358 
0.2 mM-1 s-1), was comparable to that of R74H-R147K-M212Q (kcat/KM = 0.4  0.1 mM-1 s-1), but 359 
its isopentenol titer after 48 hours (8  1 mg/L) was 135-fold less than that of R74H-R147K-360 
M212Q (1,079 mg/L). Similarly, R74G’s kcat/KM is comparable to WT’s kcat/KM, but the strain 361 
expressing R74G produced significantly higher amount of isopentenol compared to that of WT 362 
(Table 2). 363 
2.6 Effect of MVAP inhibition on PMDsc mutants for decarboxylation 364 
 The correlation analysis between isopentenol titers and kinetics of the mutants suggested 365 
that there must be other factors that determine the actual decarboxylation activity in vivo under 366 
isopentenol production conditions or growth-based selection conditions. In our previous study, 367 
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we found that the E. coli production strain containing the IPP-bypass MVA pathway and wild 368 
type PMD accumulated significantly higher concentrations of MVAP compared to that of the 369 
original pathway within 5 hours after induction (Kang et al., 2016). Assuming in vivo MVAP 370 
concentrations are well above the KM (i.e., 10x KM) for wild type PMDsc (KM(MVAP) = 2.3  0.2 371 
mM), we hypothesized that noncompetitive substrate inhibition might affect the in vivo 372 
decarboxylation activity. At such high concentrations of MVAP in vivo, the rate enhancements on 373 
kcat/KM or kcat observed in vitro for select mutants would not necessarily be observed. Considering 374 
the importance of the native mevalonate pathways for isoprenoid metabolism, the activity of 375 
PMDsc might be tightly regulated by MVAP concentrations in vivo since a low KI would 376 
significantly decrease the rate of decarboxylation as excess MVAP accumulates. This directs 377 
MVAP flux through the phosphomevalonate kinase (PMK) enzyme to generate MVAPP, the 378 
preferred native substrate for PMDsc, rather than increasing futile decarboxylation of MVAP to 379 
IP. 380 
WT and four mutants, R74G, V230E, R74G-R147K-M212Q and R74H-R147K-M212Q, 381 
were specifically selected for substrate inhibition study, where activity was measured in wide 382 
range of MVAP concentrations up to 100 mM (Figure 7). These variants representatively spanned 383 
a wide range of isopentenol titers (8 – 1,080 mg/L), and their substrate inhibition behavior was 384 
characterized by determining each mutant’s KI (Table 3). Interestingly, two higher isopentenol 385 
producing mutants (R74G and R74H-R147K-M212Q) exhibited significantly higher KI’s (110 386 
mM and 80 mM, respectively) than those with lower isopentenol producers (WT, 18 mM; 387 
V230E, 10 mM; and R74G-R147K-M212Q, 11 mM) (Figure 7). A correlation emerged between 388 
growth rates (and/or titers) and PMD activity when an observed turnover number was calculated 389 
at 100 mM MVAP using the analytical expression for noncompetitive substrate inhibition, kobs 390 
(Supplementary Figure S7). This turnover number (kobs) depends upon each mutant’s kcat, KM, and 391 
KI, perhaps yielding a more accurate assessment of the turnover conditions in vivo (Kang et al., 392 
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2016). The relationship between growth and kobs of these mutants suggests that the screening 393 
platform directly reports on the extent of substrate inhibition in PMDsc mutants (Figure 7 and 394 
Supplementary Figure S7). This sensitivity of an in vivo screening platform to a mutant’s KI 395 
modulation speaks to its power in analyzing the robustness of heterologously expressed 396 
mevalonate pathways within overexpressing bacterial strains. 397 
3 Conclusion 398 
Evaluation of enzyme libraries is often limited by the throughput of a screening method. 399 
In this regard, growth-based selection is powerful because it does not require extensive tests of an 400 
individual design, and designs with the desirable activity are enriched if the activity is essential 401 
for growth of the organism (Packer and Liu, 2015). In this study, we designed a growth-based 402 
screening platform to improve PMD decarboxylation activity toward MVAP for isopentenol 403 
production. To achieve this goal, the growth rate of the E. coli DH1 was coupled to the 404 
decarboxylation rate of MVAP (Figure 1B); the subsequent product formation of IP is ultimately 405 
converted to isopentenol via IPP-bypass MVA pathway (Figure 1A). Codon saturation 406 
mutagenesis and random mutagenesis generated two separate enzyme mutant libraries, both of 407 
which were tested by our newly developed screening platform. This growth-based screening 408 
platform identified a new set of PMDsc mutants that significantly increased isopentenol 409 
production up to 1,1305 mg/L. Correlation of growth rates and decarboxylation rates of 410 
identified PMD mutants confirmed the in vivo selectivity of the screening platform, and kinetics 411 
studies of the mutants suggested the robustness of this screening platform by providing biological 412 
context with respect to the target enzyme activity under relevant metabolite concentrations. 413 
Alteration of PMD and IPK expression levels coupled with tuning the inhibition strength of 414 
fosmidomycin provides the screening platform with more flexibility, potentially enabling further 415 
improvements of isopentenol production via the novel IPP-bypass pathway. 416 
4 Materials and Methods 417 
  
18 
4.1 Plasmids and Strains 418 
All plasmids and strains used in this study are listed in Supplementary Table S1. Primers 419 
used for construction of libraries and PMD variants are shown in Supplementary Table S2. 420 
4.2 Development of the PMD screening platform 421 
For the screening platform, a plasmid harboring 6 genes—AtoB, HMGR, HMGS, MK, 422 
Idi and a gene coding IP kinase (IPK)—was constructed by adding Idi and IPK to the plasmid 423 
(JBEI-9310) used for isopentenol production. AtoB and idi were native genes of E. coli while 424 
HMGR, HMGS, and MK were derived from S. cerevisiae. Two archaeal IP kinases 425 
from Methanothermobacter thermautotrophicus (MTH) and Thermoplasma acidophilum (THA) 426 
were amplified from two plasmids, pET15b-MTH and pET28b-THA, respectively (Funke et al., 427 
2010), using primers IPKMTH-F-BglII, IPKMTH-R-XhoI, IPKTHA-F-BglII and IPKTHA-F-428 
XhoI (Supplementary Table S2). A gene coding a potential IP kinase from E. coli (EcIPK) was 429 
amplified by using two primers EcIPK-BglII-F and EcIPK-XhoI-R (Supplementary Table S2). 430 
Wild type PMDsc and PMDsc mutants were cloned into a SC101-based plasmid under control of 431 
an araBAD promoter (PBAD) or into a ColE1-based plasmid under control of a Tet promoter (PTet) 432 
(pBbE2a) (Lee et al., 2011). Mutant libraries were transformed in DH1 containing pBbA5c-433 
MevTo-BBa1002-pTrc-MKco-EcIdi-MtIPK (JBEI-15350), and DH1 strains with libraries of 434 
PMDsc mutants were tested in the presence of fosmidomycin. 435 
4.3 Cloning and library construction 436 
Seven amino acid residues (Tyr19, Lys22, Arg74, Ile145, Ser208, Thr209, Met212) were 437 
selected for saturated mutagenesis. Tyr19, Lys22, Ser208, Thr209, and Met212 were chosen 438 
based on their vicinity to the β-phosphate group of MVAPP in a resolved crystal structure of 439 
PMDse (Barta et al., 2012) in a structural alignment of PMDsc to PMDse. Additionally, two 440 
distal residues, Arg74 and Ile145, have been shown to promote promiscuous decarboxylation 441 
activity of PMDsc toward non-native substrates (MVAP and 3-hydroxy-3-methylbutyrate (3-442 
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HMB) (Gogerty and Bobik, 2010; Kang et al., 2016). Sequences of primers used for codon 443 
saturation libraries are presented in Supplementary Table S2, and amplified PCR products 444 
containing specific saturation mutagenesis were cloned to pBbS8a vectors. 445 
Randomly mutated PMDsc sequences were generated by error-prone PCR (McCullum et 446 
al., 2010) using two primers, j5_00001_(PMDsc)_forward and j5_00002_(PMDsc)_reverse 447 
(Supplementary Table S2). The error-prone PCR buffer was supplemented with various 448 
concentrations of MgCl2 and MnCl2 to generate different mutation rates. Initially, 100 ng of 449 
JBEI-12052 (Supplementary Table S1) was used as a template for PCR, and 1 μL Taq 450 
polymerase and 1 μL of 50 mM MnCl2 (final 0.5 mM) were added just before the PCR runs. 451 
Every 5 cycles, PCR product was diluted 10-fold in fresh error-prone PCR buffer and additional 1 452 
μL Taq polymerase and 1 μL 50 mM MnCl2 (Final would be 0.5 mM) was added to 100 μL PCR 453 
reactions. To prepare low-mutation-rate libraries, a few PCR reactions were prepared with lower 454 
concentration of MnCl2 and/or MgCl2 with only 5 cycles. All PCR products were digested with 455 
DpnI to remove the template plasmids. Purified PCR products were assembled into pBbE2a by 456 
Gibson assembly. 457 
Randomly mutated PMDsc sequences were grouped into three libraries according to their 458 
mutation rates, low (1-2 bases per coding sequence (CDS)), mid (3-4 bases per CDS) and high 459 
(more than 10 bases per CDS) mutation rates. These three libraries were transformed in the 460 
screening host strain DH1 and three colony-full plates were used for the screening. Number of 461 
colonies on each plate was estimated to around 103-104. 462 
4.4 Screening procedures and conditions 463 
Saturation mutagenesis libraries of PMDsc cloned into a SC101-based plasmid under 464 
control of an araBAD promoter (PBAD) were transformed into in E. coli DH1 strains harboring 465 
JBEI-15350 (Supplementary Table S1). Cultures were suspended in EZ-Rich medium containing 466 
1 % glucose, 0.1 mM IPTG, 30 μg/mL chloramphenicol (Cm) and 100 μg/mL ampicillin (Amp), 467 
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and incubated at 37 °C at 200 rpm overnight. These cultures were diluted to OD 0.3 in 500 μL 468 
EZ-rich medium containing 1 % glucose, 0.1mM IPTG, 50 μM fosmidomycin, and 10mM 469 
arabinose. 500 μL cell cultures were prepared in 96 deep-well plates and incubated at 37°C with a 470 
shaking speed of 700 rpm in a rotary shaking incubator (HT Infors Multitron; 44% humidity). 471 
After 16-18 hours of incubation (Day 2), the overnight cultures were diluted again to OD 0.1 in 472 
fresh 500 μL EZ-rich medium containing 1 % glucose, 0.1 mM IPTG, 50 μM fosmidomycin and 473 
10mM arabinose. 500 μL cell cultures were prepared in 96 deep-well plates incubated at 474 
37°C and a shaking speed of 700 rpm in a rotary shaking incubator (HT Infors multitron; 700 475 
rpm, 37°C, 44 % humidity) for 8-16 hours. Next day (Day 3), the overnight cultures were diluted 476 
to initial OD of 0.05 in 200 μL EZ-rich medium containing 1 % glucose, 0.1mM IPTG, 50 μM 477 
fosmidomycin and 10mM arabinose, and the optical density at 600 nm were obtained in the 96-478 
well plates incubated at 37°C at a shaking speed of 173 rpm (linear, 1 amplitude) in a Tecan 479 
F200Pro microplate reader (Tecan, USA). 480 
Random mutagenesis library of PMDsc was cloned into a ColE1-based plasmid under 481 
control of a Tet promoter (PTet) and transformed into E. coli DH1 strains harboring pBbA5c-482 
MevTo-BBa1002-pTrc-MKco-EcIdi-MtIPK (JBEI-15350, Supplementary Table S1). DH1 strains 483 
with the random mutagenesis library were re-suspended and diluted to OD 0.2 in 100 μL of EZ-484 
Rich medium containing 1 % glucose, 0.1 mM IPTG, 30 μg/mL Cm, and 100 μg/mL Amp, 50 485 
μM fosmidomycin, and 100 nM anhydrotetracycline (aTc). Cell cultures were prepared in 96-well 486 
plates (Nunc) and incubated at 37 °C with shaking speed of 173 rpm (linear, 1 amplitude) in a 487 
Tecan F200Pro microplate reader (Tecan, USA). After 24 hours of incubation (Day 2), the 488 
overnight cultures were diluted 100-fold in 2 mL EZ-rich medium containing 1 % glucose, to 489 
recover surviving strains. The overnight cultures were challenged again by diluting them to OD 490 
0.05 in 100 μL EZ-rich medium containing 1 % glucose, 0.1 mM IPTG, 50 μM fosmidomycin, 491 
and 10 nM aTc. The 96-well plates were incubated at 37°C at a shaking speed of 173 rpm (linear, 492 
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1 amplitude) in a Tecan F200Pro microplate reader (Tecan, USA), and cell cultures were 493 
subsequently diluted to OD 0.05 once growth reached the exponential phase. The dilutions were 494 
continued until the growth rate of all libraries reached that of R74H. 495 
4.5 Isopentenol production in E. coli 496 
For isopentenol production, E. coli DH1 was transformed with two plasmids (JBEI-9310 497 
and pTrc99a plasmids expression PMDsc variants; Supplementary Table S1), and isopentenol 498 
production was performed as previously described (Kang et al., 2016). Briefly, seed cultures were 499 
prepared from single colonies, grown overnight and diluted to OD 0.05 in EZ-Rich defined 500 
medium (Teknova, USA) containing 10 g/L glucose (1 %, w/v), 100 μg/mL ampicillin, and 30 501 
μg/mL chloramphenicol. Cell cultures (5 mL) were grown at 37°C at a shaking speed of 200 rpm. 502 
At OD600 of 0.4-0.6, 0.5 mM IPTG was added to the cell cultures to induce expression of genes 503 
from the two plasmids, and the cultures were incubated at 30°C and 200 rpm for up to 48 hours. 504 
For isopentenol quantitation, an aliquot of cell cultures (270 μL) was combined with 270 μL ethyl 505 
acetate containing 1-butanol (30 mg/L) as an internal standard, and the mixture were vigorously 506 
mixed for 15 min to extract isopentenol in the cell culture to the ethyl acetate. After extraction, 507 
cells were centrifuged at 20,000 x g for 2 minutes, and 100 μL of the ethyl acetate layer was 508 
diluted 5-fold in ethyl acetate containing 1-butanol (30 mg/L). An aliquot (1 μL) of each of the 509 
diluted samples was analyzed by Thermo GC-FID equipped with DB-WAX column (Agilent, 510 
USA). 511 
4.6 Protein expression and purification 512 
Protein expression and purification protocols were performed in a manner similar 513 
previously published with minor modifications (Kang et al., 2016). Namely, PMDsc mutant 514 
plasmids were harbored in the Rosetta (DE3) bacterial strain as opposed to the BL21(DE3) strain 515 
(Supplementary Table S1). Seed cultures were grown and harvested in Terrific Broth medium 516 
with 2% glycerol containing 50 mg/L kanamycin and 30 mg/L chloramphenicol. Cells were 517 
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initially grown at 37oC with shaking at 200 rpm until the OD600 reached 0.6 - 0.8. Thereafter, the 518 
cell cultures were induced with 0.5 mM IPTG and incubated overnight at 18oC. 519 
Cells were pelleted by centrifuging at 5,524 x g for 10 minutes at 4oC; cell lysis was 520 
prompted by suspending cell pellets in 50 mM Tris-HCl (pH 8.2) containing 300 mM NaCl, 10 521 
mM imidazole, and 1 mg/mL lysozyme (Sigma). The lysates were centrifuged for 30 minutes at 522 
15,344 x g and loaded directly onto a 1 mL HisTrap FF column. After washing with 15 column 523 
volumes of lysis buffer, the His-tagged PMDsc was eluted using 50 mM Tris-HCl (pH 7.5), 300 524 
mM NaCl, and 240 mM imidazole. The eluent proteins were concentrated to 100-500 M using a 525 
Millipore 30,000 MWCO spin column, snap frozen in liquid nitrogen, and stored at -80oC. The 526 
activity for wild type PMDsc containing higher salt concentrations was measured to be within 527 
error of that found for PMDsc prepared with a desalting step (Kang et al., 2016), which was 528 
omitted along with supplementation of purified enzyme with dithiothreitol and glycerol. 529 
4.7 Enzyme characterization and kinetics of PMD 530 
In vitro enzyme kinetics of PMDsc were performed as described in the previous study 531 
(Kang et al., 2016). Briefly, enzymatic activity was determined by a spectrophotometric assay 532 
quantifying ADP product formation via the pyruvate kinase/lactate dehydrogenase coupled 533 
enzyme assay. Assay mixtures were prepared in 150 µL total volume containing 50 mM HEPES-534 
KOH (pH 7.5), 10 mM MgCl2, 400 μM phosphoenolpyruvate, 400 μM NADH, 4 mM ATP, and 535 
25 U of pyruvate kinase/lactate dehydrogenase. The reaction was initiated by enzyme after 536 
incubating PMDsc substrate and cofactor for fifteen minutes with coupled assay components. The 537 
MVAP was varied from 0.100 - 4.0 mM, and the reaction velocity was determined by monitoring 538 
the absorbance at 340 nm in a Spectramax 384plus microplate reader (Molecular Devices, USA). 539 
To obtain kinetic data relevant to non-competitive substrate inhibition, MVAP was varied from 540 
0.100 - 100 mM. Enzyme concentration ( = 56,630 M-1 cm-1) was determined 541 
spectrophotometrically at 280 nm with a NanoDrop ND-1000 spectrophotometer. kcat and KM 542 
  
23 
were derived for PMDsc mutants by fitting the initial velocities measured from 0.100 - 4.0 mM 543 
MVAP to the Michaelis-Menten equation; KI was determined for select mutants by fitting initial 544 
velocities measured from 0.100 - 100 mM MVAP to the non-competitive substrate inhibition 545 
equation. All kinetic analysis was performed in Graphpad Prism, version 7.0a. 546 
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Table 1  Mutated residues found in 15 replicates of random mutagenesis libraries. All 636 
mutations were confirmed by sequencing, and three libraries (L8, L9, L15) included silent 637 
mutations. Number of silent mutations refers to number of mutated nucleotides without altering 638 
wild type amino acids. 639 
 640 
ID Mutated Residues Number of silent mutations 
L1 Q210H 
 
L2 R74G, R147K 
 
L3 Wild type 
 
L4 Wild type 
 
L5 V230E 
 
L6 Q210H 
 
L7 S186C 
 
L8 Q140L, I226V 3 
L9 R74G, E144D 3 
L10 Wild type 
 
L11 Wild type 
 
L12 Q210H 
 
L13 Q210H 
 
L14 Q210H 
 
L15 R74G, E144D 4 
 641 
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Table 2  Enzyme kinetics (kcat, KM and kcat/KM), growth rates (hr-1) and isopentenol titers (at 642 
48 hr, mg/L) of PMDsc mutants. N.D.: not detected. The numbers in brackets are either standard 643 
errors (kinetics) or standard deviation (growth rates and titers). 644 
Mutant 
kcat,  
sec-1 
KM,  
mM 
kcat/KM,  
mM-1 sec-1 
Growth rate, 
hr-1 
48hr Titer, 
mg/L 
WT 0.15 (0.01) 2.3 (0.2) 0.066 (0.007) 0.39 (0.02) 475 (40) 
Y19H 0.27 (0.01) 0.35 (0.02) 0.78 (0.06) 0.22 (0.01) 388 (9) 
K22Y 0.09 (0.01) 1.3 (0.3) 0.12 (0.03) 0.13 (0.11) 22 (8) 
R74G 0.14 (0.02) 3.4 (1.0) 0.04  (0.01) 0.81 (0.03) 975 (96) 
R74H 0.33 (0.03) 0.75 (0.05) 0.44 (0.05) 0.68 (0.04) 770 (263) 
I145A 0.029 (0.004) 2 (1) 0.01 (0.01) 0.17 (0.00) 623 (140) 
R147K 0.149 (0.006) 0.5 (0.1) 0.32 (.09) 0.56 (0.02) 793 (22) 
S186C 0.07 (0.01) 0.8 (0.2) 0.08 (0.02) 0.30 (0.02) 596 (110) 
M212Q 0.35 (0.02) 0.7 (0.2) 0.5 (0.1) 0.09 (0.01) 601 (76) 
I226V 0.16 (0.01) 0.34 (0.06) 0.46 (.09) 0.35 (0.01) 633 (53) 
V230E 0.07 (0.01) 0.8 (0.2) 0.08 (0.02) 0.21 (0.18) 278 (91) 
R74G-R147K 0.22 (0.01) 0.53 (0.05) 0.42 (0.05) 0.84 (0.04) 909 (25) 
R74H-R147K-M212Q 0.16 (0.02) 0.4 (0.2) 0.4 (0.1) 0.79 (0.03) 1079 (27) 
R74G-R147K-M212Q 0.22 (0.04) 0.5 (0.1) 0.5 (0.2) N. D.  8 (1) 
R74G-R147K-Q140L 0.06 (0.01) 2(1) 0.03 (0.02) N. D.  401 (10) 
 645 
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Table 3 Analysis of Ki and kobs for select mutants. N.D.: not detected. 647 
 648 
 
kcat,  
sec-1 
KM, 
mM 
Ki, 
mM 
kobs,  
sec-1 
Growth rate,  
hr-1 
48hr Titer, 
mg/L 
WT 0.15 2.3 18 0.02 (0.01) 0.39 (0.02) 475 (40) 
R74G 0.14 3.4 110 0.07 (0.04) 0.81 (0.03) 975 (96) 
V230E 0.07 0.8 10 
0.006 
(0.004) 
0.2 (0.2) 278 (91) 
R74G-R147K-M212Q 0.22 0.5 11 
0.022 
(0.008) 
N.D. 8 (1) 
R74H-R147K-M212Q 0.16 0.43 80 0.07 (0.03) 0.79 (0.03) 1079 (27) 
  649 
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List of Figures 650 
Figure 1 Schematic diagrams of (A) the IPP-bypass isopentenol pathway catalyzed by 651 
AtoB, HMGS, HMGR, MK and PMD (solid arrows) and three reactions by PMK, PMD and 652 
NudB (dotted arrows) included in the original MVA pathway, and (B) design of the pathways for 653 
screening platform, which includes IP kinase (IPK) and IPP isomerase (Idi) in addition to 5 654 
reactions in IPP-bypass isopentenol pathway. Abbreviations: Ac-CoA, acetyl-CoA; AAc-CoA, 655 
acetoacetyl-CoA; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA; MVA, mevalonate; MVAP, 656 
mevalonate phosphate; MVAPP, mevalonate diphosphate; IPP, isopentenyl diphosphate; IP, 657 
isopentenyl monophosphate. 658 
Figure 2  Development and optimization of the screening platform (A) Test of three 659 
isopentenyl phosphate (IP) kinases with wild type PMDsc (WT) or S208E mutant: EcIPK, IP 660 
kinase from E. coli; MtIPK, IP kinase from Methanothermobacter thermautotrophicus; Ta IPK, 661 
IP kinase from Thermoplasma acidophilum. Two concentrations of aTc (10 nM and 100 nM) 662 
were used for expression of PMD genes. (B) Test of four PMDsc sequences (WT, K22M, R74H 663 
and S208E) with MtIPK. Expression of four PMDsc mutants were induced by 10mM arabinose. 664 
Relative growth rate (h-1) and relative activity were on the table. Shaded area is standard error of 665 
four biological replicates. 666 
Figure 3 Screening of targeted saturation mutagenesis library (A) Residues for saturation 667 
mutagenesis including Tyr19, Lys22, Arg74, Ser208, Thr209 and Met212; MVAP, mevalonate 668 
phosphate; ATP, adenosine triphosphate. (B-C) Isopentenol production titers of single mutants 669 
(B) and double mutants (C) including R74H, which was previously identified. Light grey bars are 670 
titers measured 24 hours after induction and dark grey bars are titers after 48 hours of induction. 671 
The reference line is the titer of wild type PMDsc (WT) 48 hours after induction. Titers were 672 
calculated with three biological replicates (n = 3). 673 
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Figure 4 Screening of random mutagenesis library. (A) Isopentenol titers produced from 674 
DH1 strains containing JBEI-9310 (Supplementary Table 1) and various PMDsc mutants 675 
concurrently identified from random mutagenesis libraries and (B) single mutant of the identified 676 
residue. (C) Triple mutants were generated based on promising residues identified in this study 677 
and the previous study (Kang et al., 2016). The reference line at 475.1 mg/L is isopentenol titer of 678 
wild type PMDsc (WT) after 48 hours induction and thicker reference line at 1079.1 mg/L is 679 
maximum isopentenol titer of the mutant, R74H-M212Q-R147K after 48 hours of induction. 680 
Light grey bars are titers after 24 hours induction and dark grey bars are titers after 48 hours of 681 
induction. Titers were calculated with three biological replicates (n = 3). 682 
Figure 5 A cartoon representation of PMDsc structure with the 9 identified residues in this 683 
study. Four helix secondary structures are highlight with the substrate, MVAP: α-helix 1 (H1, 684 
skyblue), α-helix 2 (H2, mustard); α-helix 4 and α-helix 5 (H4-H5, purple). 685 
Figure 6. Isopentenol titers and growth rates of 21 mutants (filled circles) with standard 686 
deviation of three biological replicates. Two reference lines (dotted) are wild type’s growth rate 687 
(0.4) and isopentenol titer (475 mg/L). R2 and the trend line (solid) were generated by linear 688 
regression. 689 
Figure 7 Determination of the noncompetitive substrate inhibition constant, KI, for select 690 
PMDsc mutants: WT (circles); R74G (squares); V230E (upward triangles); 691 
R74G:R147K:M212Q (downward triangles); R74H:R147K:M212Q (diamonds). All activities 692 
reported are normalized relative to each mutant’s kcat derived from fits to the noncompetitive 693 
substrate inhibition expression.  Parameters were derived from three technical replicates (n = 3).   694 
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List of Supplementary Tables and Figures 695 
Supplementary Table S1 List of strains and plasmids 696 
Supplementary Table S2 List of primers to generate mutagenesis 697 
Supplementary Figure S1 Susceptibility test of three E. coli strains (BW25113, DH1 and 698 
BL21 (DE3)) treated with four different concentration of fosmidomycin (FOS): 0, 10, 50 and 100 699 
nM FOS. Shaded area is standard error of three biological replicates. 700 
Supplementary Figure S2 Test of four PMDsc sequences (WT, K22M, R74H and S208E) 701 
with MtIPK. Expression of four PMDsc mutants were induced by (A) 10 nM aTc or (B) 100 nM 702 
aTc. Shaded area is standard error of three biological replicates. The included table (C) shows 703 
relative growth rate and activity of each PMDsc variants. 704 
Supplementary Figure S3 Chromatogram of 4 nucleotides (A, green; C, blue; G, black; and 705 
T, red) detected at the two residues, Lys22 (K22) and Arg74 (R74). Arrow indicates that intensity 706 
of nucleotides coding arginine (TCT) decreased residue 74 over time while those of histidine 707 
(ATG) increased (Left column), suggesting DH1 with PMDsc R74H has become dominant. One 708 
the other hand, nucleotides coding methionine (CAT) at residue 22 was substituted back to wild 709 
type lysine (TTT), suggesting that DH1 with expression PMDsc K22M was outcompeted by 710 
either wild type or R74H mutants. Intensity of nucleotides at two residues was monitored for 711 
three days (Day 1 to Day 3), and codon of four amino acids are written in reverse-complement. 712 
Supplementary Figure S4 Space filling model showing a potential gatekeeper interaction 713 
between Arg74 (blue spheres) and a substrate binding loop (green spheres) that shields the active 714 
site from bulk solvent. 715 
Supplementary Figure S5 Chromatogram of nucleotides (A, green; C, blue; G, black; and 716 
T, red) detected at residue 208 and 209 after the screening. Saturated mutagenesis libraries of two 717 
wild type residues, Ser208 and Thr209 were constructed by substituting the residue with NNK. 718 
  
32 
Arrow indicates positions of randomized nucleotides for Ser208 (CGA) or Thr209 (CGT). Mixed 719 
signals of nucleotides at T209 residue (grey arrows) indicates that there was relatively less 720 
selection pressure on residue 209 as the mixed nucleotides represents co-existence of various 721 
mutants. However, serine clearly dominated at residue 208 (blue arrows; CGA or AGA). N 722 
represents all 4 nucleotides and codons of amino acids are written in reverse-complement due to 723 
sequencing direction. 724 
Supplementary Figure S6 Cartoon representation of PMDsc with location of essential 725 
residues. α-helix 2 (H2, mustard) includes Ser120, Ser121, Ser155 and Arg158 and α-helix 4 (H4, 726 
purple) includes Ser208. All serine residues and Arg158 have critical roles in stabilization of 727 
substrates including mevalonate diphosphate (MVAP). Grey area is the surface representation of 728 
the nearby molecules. 729 
Supplementary Figure S7 Relationship between kcat and cellular growth rates (A); and 48hr 730 
isopentenol titers (B) for the characterized PMDsc mutants. Shown in (C) and (D) are the same 731 
respective relationships between the observed turnover number, kobs, calculated using non-732 
competitive substrate inhibition at 100 mM MVAP. 733 
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